Tatsunori Minamide
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tatsunori Minamide has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Hiroaki Ikematsu
Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
1 shared publication- Keiichiro Nakajo
Division of Science and Technology for Endoscopy, Exploratory Oncology Research and Clinical Trial Center National Cancer Center Kashiwa Japan
1 shared publication - Kenji Takashima
Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
1 shared publication Kensuke Shinmura
Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
1 shared publication- Tomohiro Kadota
Department of Gastroenterology and Endoscopy National Cancer Center Hospital East Kashiwa Chiba Japan
1 shared publication Tomonori Yano
Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
1 shared publication
Latest Publications
- Open Access
- 24 June 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2785
Clinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer
Photodynamic therapy (PDT) using a conventional photosensitizer was approved for esophageal cancer in the early 1990s; however, it was replaced by other conventional treatment modalities in clinical practice because of the high frequency of cutaneous phototoxicity and esophageal stricture after the procedure. The second-generation photosensitizer, talaporfin sodium, which features more rapid clearance from the body, was developed to reduce skin phototoxicity, and talaporfin sodium can be excited at longer-wavelength lights comparing with a conventional photosensitizer. Endoscopic PDT using talaporfin sodium was initially developed for the curative treatment of central-type early lung cancer in Japan, and was approved in the early 2000s. After preclinical experiments, PDT using talaporfin sodium was investigated for patients with local failure after chemoradiotherapy, which was the most serious unmet need in the practice of esophageal cancer. According to the favorable results of a multi-institutional clinical trial, PDT using talaporfin sodium was approved as an endoscopic salvage treatment for patients with local failure after chemoradiotherapy for esophageal cancer. While PDT using talaporfin sodium is gradually spreading in clinical practice, further evaluation at the point of clinical benefit is necessary to determine the importance of PDT in the treatment of esophageal cancer.
- 24 June 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2785
Open AccessClinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer
Photodynamic therapy (PDT) using a conventional photosensitizer was approved for esophageal cancer in the early 1990s; however, it was replaced by other conventional treatment modalities in clinical practice because of the high frequency of cutaneous phototoxicity and esophageal stricture after the procedure. The second-generation photosensitizer, talaporfin sodium, which features more rapid clearance from the body, was developed to reduce skin phototoxicity, and talaporfin sodium can be excited at longer-wavelength lights comparing with a conventional photosensitizer. Endoscopic PDT using talaporfin sodium was initially developed for the curative treatment of central-type early lung cancer in Japan, and was approved in the early 2000s. After preclinical experiments, PDT using talaporfin sodium was investigated for patients with local failure after chemoradiotherapy, which was the most serious unmet need in the practice of esophageal cancer. According to the favorable results of a multi-institutional clinical trial, PDT using talaporfin sodium was approved as an endoscopic salvage treatment for patients with local failure after chemoradiotherapy for esophageal cancer. While PDT using talaporfin sodium is gradually spreading in clinical practice, further evaluation at the point of clinical benefit is necessary to determine the importance of PDT in the treatment of esophageal cancer.
- 17 May 2019
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 90 (3) , 529-531
Early-stage primary signet ring cell carcinoma of the colon with magnifying endoscopic findings
- 17 May 2019
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 90 (3) , 529-531
Early-stage primary signet ring cell carcinoma of the colon with magnifying endoscopic findings